Skip to main content
SpringerLink
Log in

Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma

Southwest Oncology Group study 8712

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EF: 2,4-Diamino-5-methyl-6-, (3,4,5-trimethoxyanilino) methyl, quinazoline (TMQ), a potent nonclassical folate antagonist inhibitor. I. Effect on dihydrofolate reductase and growth of rodent tumorsin vitro andin vivo. Biochem Pharmcol 28:1983–1987, 1979

    Article  Google Scholar 

  2. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6- [(3,4,5-trimethoxyanilino)-methyl]quinazoline), a nonclassical antifolate in methotrexate-resistant leukemia cellsin vitro. Biochem Pharmacol 33:1697–1699, 1984

    PubMed  Google Scholar 

  3. Diddens H, Neithammer D, Jackson RC: Patterns of crossresistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43:5286–5292, 1983

    PubMed  Google Scholar 

  4. Balis FM, Lester CM, Poplack DG: Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 46: 169–174, 1986

    PubMed  Google Scholar 

  5. Scanlon K, Ohnuma T, Lo RJ, Nichol CA, Waxman S, Greenspan EM, Holland JF: Effects of 2,4-diamino-6- (2,5-dimethoxybenzyl)-5-methyl-pyrido (2,3-D) pyrimidine (BW301U) on methotrexate (MTX)-resistant human acute lymphoblastic leukemia (ALL) cell lines. Proc Am Soc Oncol 23:12, 1982

    Google Scholar 

  6. Clinical Brochure on Trimetrexate Glucuronate (TMTX), NSC 352122. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute. 1983

Download references

Author information

Authors and Affiliations

  1. Associates in Hematology and Oncology, Fort Myers, FL

    Walter H. Harvey & Janice H. Harvey

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Thomas R. Fleming & Phyllis J. Goodman

  3. Puget Sound Oncology Consortium, Seattle, WA

    Saul E. Rivkin

  4. Temple University, Philadelphia, PA, USA

    John S. MacDonald

Authors
  1. Walter H. Harvey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas R. Fleming
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phyllis J. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janice H. Harvey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Saul E. Rivkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John S. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harvey, W.H., Fleming, T.R., Goodman, P.J. et al. Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Invest New Drugs 11, 45–46 (1993). https://doi.org/10.1007/BF00873909

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873909

Key words

Search

Navigation